LEXICON PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost (Deprecated 2012-01-31)
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost (Deprecated 2012-01-31) of $1.60 million for the 3-month period ending 2012-06-30, per its 10-Q filed 2012-08-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationCost · last filed 2012-08-02
- LEXICON PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, compensation cost (deprecated 2012-01-31) for the quarter ending 2012-06-30 was $1.60M, a 6.67% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, compensation cost (deprecated 2012-01-31) for the quarter ending 2011-06-30 was $1.50M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost (Deprecated 2012-01-31) 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost (Deprecated 2012-01-31) 6 month |
|---|---|---|
| 2012-06-30 | $1.60M 10-Q · filed 2012-08-02 | $3.30M 10-Q · filed 2012-08-02 |
| 2011-06-30 | $1.50M 10-Q · filed 2012-08-02 | $2.90M 10-Q · filed 2012-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |